Abstract Details

Title Neisseria Sicca Sepsis Associated with Ravulizumab for Myasthenia Gravis: Case Report

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P10 - Poster Session 10 (5:00 PM-6:00 PM)

Poster/Presentation
Number 11-008

Objective To document a previously unreported case of N.sicca sepsis associated with ravulizumab in a patient with myasthenia gravis (MG).

Background As novel therapeutics emerge such as the complement-based inhibitor ravulizumab, diligent post-marketing surveillance is important as these agents put patients at greater risk of encapsulated bacterial infections. We present a case report of a generalized myasthenia gravis (MG) patient on ravulizumab who suffered serious N. sicca bacteremia while on this complement modulator.

Design/Methods NA

Results This patient had serum anti-AchR antibody positive generalized MG. He was on active treatment with ravulizumab q8 week infusions, azathioprine 100mg, prednisone 2.5mg and pyridostygmine 60mg three times a day. He was hospitalized for an acute febrile illness, with blood cultures x 2 positive for N. sicca. He was treated with antimicrobials including IV ceftriaxone for 14 days. No identifiable source for infection was identified.

Conclusions This case demonstrates that in addition to increasing risk of meningococcal infection, for which patients receiving complement inhibitors are pre-vaccinated, these agents also pose risk of other encapsulated bacterial infections, for which protection is not available.

Authors/Disclosures
Shaida Omid, MD PRESENTER	Dr. Omid has nothing to disclose.
David M. Simpson, MD, FAAN (Icahn School of Medicine at Mount Sinai)	Dr. Simpson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Simpson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz.

��ɫ��

��ɫ��